Gastrointestinal Tumors Clinical Trial
Official title:
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
This is a Phase 1, open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study of PF-07062119 administered as a single agent in sequential dose levels and then in combination with anti-programmed cell death -1 protein (anti-PD-1) and in combination with an anti-vascular endothelial growth factor (anti-VEGF). In Part 1A, successive cohorts of patients will receive escalating doses of PF-007062119 and then in dose finding (Part 1B) with PF-07062119 in combination with anti-PD-1 and in combination with anti-VEGF. This study contains 2 parts, dose escalation with single agent (Part 1A) and then dose finding with PF-007062119 in combination with ant-PD-1 and in combination with anti-VEGF (Part 1B) followed by dose expansion arms as a single agent and PF-07062119 in combination with anti-PD 1 and in combination with anti-VEGF (Part 2). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05922358 -
Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors
|
Phase 2 | |
| Recruiting |
NCT06152757 -
BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors
|
Early Phase 1 | |
| Completed |
NCT01552291 -
The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies
|
Phase 4 | |
| Active, not recruiting |
NCT03833700 -
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
|
Phase 1 | |
| Recruiting |
NCT06085365 -
Effects of Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors
|
Phase 3 | |
| Completed |
NCT01640665 -
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
|
Phase 1 | |
| Recruiting |
NCT04629326 -
PD-L1 Targeting Molecular Imaging of Solid Tumors
|
N/A | |
| Recruiting |
NCT05981235 -
Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors
|
Phase 1 | |
| Recruiting |
NCT05262335 -
Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)
|
Phase 2 | |
| Terminated |
NCT01648465 -
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT06263205 -
Wound Management Following Gl Tumor Surgery: Comparing Outcomes of Dressing Changes Versus Non-Dressing Techniques
|
N/A |